

6 June 2019

SECTION 708A NOTICE: SHARE AND OPTION ISSUE

Anteo Diagnostics Limited (ASX: ADO) (“Anteo” or “the Company”) hereby provides notice to the ASX for the purpose of section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**) that it has issued 331,950,823 ordinary fully paid shares and 195,187,019 Quoted Options (\$0.02 @ 6-Dec-20), per the attached Appendix 3B.

The Company states pursuant to the provisions of section 708A(5)(e) of the Corporations Act that:

- the Securities were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- this notice is being given under section 708A(5)(e) of the Corporations Act;
- as at the date of this notice, it has complied with the relevant provisions of Chapter 2M of the Corporations Act as they apply to the Company and Section 674 of the Corporations Act; and
- as at the date of this notice, there is no excluded information, as that term is defined in Sections 708A(6)(e), 708A(7) and 708A(8) of the Corporations Act.

On behalf of the Board
Duncan Cornish
Company Secretary

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX)

Anteo Group is a surface chemical company with Intellectual Property (“IP”) in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company’s purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Anteo’s customers operate in the life sciences, diagnostics, energy and medical devices markets.

For more information, please contact:

Harley Frankfurt, Chief Executive Officer, Anteo Diagnostics Limited: +61 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

Follow Anteo Diagnostics on Twitter:



<https://twitter.com/AnteoDX> or visit www.anteotech.com

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

ANTEO DIAGNOSTICS LIMITED

ABN

75 070 028 625

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	+Class of +securities issued or to be issued	(i) Ordinary Shares (ii) Quoted Options
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	(i) 331,950,823 Ordinary Shares (ii) 195,187,019 Quoted Options
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	(i) 331,950,823 Ordinary Shares (ii) 195,187,019 Quoted Options, exercisable at \$0.02 each on or before 6-Dec-20

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

<p>4 Do the *securities rank equally in all respects from the *issue date with an existing +class of quoted *securities? If the additional *securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>(i) Ordinary Shares = Yes (ii) Quoted Options = No, a new class of quoted options is being issued. Upon exercise of the options into fully paid ordinary shares, they will rank equally with ordinary shares on issue</p>
<p>5 Issue price or consideration</p>	<p>(i) \$0.011 per share (ii) Options issued for nil consideration</p>
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>The following securities are issued pursuant to the Company's Renounceable Rights Issue:</p> <ul style="list-style-type: none"> - 231,951,315 Ordinary Shares - 115,975,579 Quoted Options <p>The following securities are issued pursuant to a private placement:</p> <ul style="list-style-type: none"> - 99,999,508 Ordinary Shares - 49,999,724 Quoted Options <p>The following securities are being issued to the Underwriter of the Rights Issue as part of their fee arrangements:</p> <ul style="list-style-type: none"> - 29,211,716 Quoted Options
<p>6a Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the *securities the subject of this Appendix 3B</i>, and comply with section 6i</p>	<p>Yes</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>16 November 2018</p>
<p>6c Number of *securities issued without security holder approval under rule 7.1</p>	<p>79,211,440 Quoted Options</p>
<p>6d Number of *securities issued with security holder approval under rule 7.1A</p>	<p>99,999,508 Ordinary Shares</p>

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil										
6f	Number of *securities issued under an exception in rule 7.2	231,951,315 Ordinary Shares and 115,975,579 Quoted Options issued under Exception 1 to rule 7.2										
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	<ul style="list-style-type: none"> - Issue date: 6-Jun-19 - Issue price: \$0.011 per Share - 15 Day VWAP: \$0.0140 (75% = \$0.0105) - Source: Miraql Reporting Software 										
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A										
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining Issue Capacity: <ul style="list-style-type: none"> - Rule 7.1 = 121,494,743 - Rule 7.1A = 38,471,281 										
7	*Issue dates <small>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B.</small>	6 June 2019										
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Number</th> <th style="text-align: left;">*Class</th> </tr> </thead> <tbody> <tr> <td>1,491,707,400</td> <td>Ordinary Shares</td> </tr> <tr> <td>195,187,019</td> <td>Quoted Options (\$0.02 @ 6-Dec-20)</td> </tr> </tbody> </table>	Number	*Class	1,491,707,400	Ordinary Shares	195,187,019	Quoted Options (\$0.02 @ 6-Dec-20)				
Number	*Class											
1,491,707,400	Ordinary Shares											
195,187,019	Quoted Options (\$0.02 @ 6-Dec-20)											
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left;">Number</th> <th style="text-align: left;">*Class</th> </tr> </thead> <tbody> <tr> <td>4,000,000</td> <td>Options (0.01c @ 30-Sep-19) Vest VWAP 2.98c</td> </tr> <tr> <td>4,000,000</td> <td>Options (0.01c @ 30-Sep-19) Vest VWAP 4.25c</td> </tr> <tr> <td>3,000,000</td> <td>Options (0.01c @ 23-Apr-23) Vest VWAP 3.710c</td> </tr> <tr> <td>6,000,000</td> <td>Options (0.01c @ 23-Apr-23) Vest VWAP 5.566c</td> </tr> </tbody> </table>	Number	*Class	4,000,000	Options (0.01c @ 30-Sep-19) Vest VWAP 2.98c	4,000,000	Options (0.01c @ 30-Sep-19) Vest VWAP 4.25c	3,000,000	Options (0.01c @ 23-Apr-23) Vest VWAP 3.710c	6,000,000	Options (0.01c @ 23-Apr-23) Vest VWAP 5.566c
Number	*Class											
4,000,000	Options (0.01c @ 30-Sep-19) Vest VWAP 2.98c											
4,000,000	Options (0.01c @ 30-Sep-19) Vest VWAP 4.25c											
3,000,000	Options (0.01c @ 23-Apr-23) Vest VWAP 3.710c											
6,000,000	Options (0.01c @ 23-Apr-23) Vest VWAP 5.566c											

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

Number	+Class
6,000,000	Options (0.01c @ 23-Apr-23) Vest VWAP 9.276c
23,000,000	Total

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

11 Is security holder approval required?

12 Is the issue renounceable or non-renounceable?

13 Ratio in which the *securities will be offered

14 *Class of *securities to which the offer relates

15 *Record date to determine entitlements

16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

17 Policy for deciding entitlements in relation to fractions

18 Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

20 Names of any underwriters

21 Amount of any underwriting fee or commission

22 Names of any brokers to the issue

23 Fee or commission payable to the broker to the issue

+ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	*Issue date	

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of *securities
(tick one)

(a) *Securities described in Part 1

(b) All other *securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders

36 If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

37 A copy of any trust deed for the additional *securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of *securities for which *quotation is sought

39 *Class of *securities for which quotation is sought

40 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another *security, clearly identify that other *security)

	Number	*Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	

+ See chapter 19 for defined terms.

Appendix 3B

New issue announcement

Quotation agreement

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

DP Cornish
Company Secretary
6 June 2019

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	1,152,756,577
Add the following: <ul style="list-style-type: none"> • Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid +ordinary securities that became fully paid in that 12 month period Note: <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	231,951,315
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	-
“A”	1,384,707,892

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

Step 2: Calculate 15% of "A"	
"B"	0.15
<i>Multiply "A" by 0.15</i>	207,706,183
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p>Note:</p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	86,211,440
"C"	86,211,440
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15 <i>Note: number must be same as shown in Step 2</i>	207,706,183
Subtract "C" <i>Note: number must be same as shown in Step 3</i>	86,211,440
Total ["A" x 0.15] – "C"	121,494,743

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	1,384,707,892
Step 2: Calculate 10% of “A”	
“D”	0.10
Multiply “A” by 0.10	138,470,789
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A <i>Notes:</i> <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	99,999,508
“E”	99,999,508
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	138,470,789
Subtract “E” <i>Note: number must be same as shown in Step 3</i>	99,999,508
Total [“A” x 0.10] – “E”	38,471,281

+ See chapter 19 for defined terms.